You are here

AstraZeneca

AstraZeneca rejigs commercial ranks around cancer, biopharma in wake of Mallon's departure

Fierce Pharma

Tue, 01/8/19 - 09:18 am

Ironwood names AstraZeneca exec as CEO; shares up 8%

Seeking Alpha

Sat, 01/5/19 - 01:41 pm

Ironwood Pharmaceuticals

New Class of Breast Cancer Drugs Could Help Treat Toughest Lung Cancer Cases

BioSpace

Fri, 12/28/18 - 01:30 pm

Bristol-Myers Squibb

Myriad Genetics' New FDA Nod for BRACAnalysis CDx Widens Base

Yahoo/Zacks.com

Thu, 12/20/18 - 10:16 am

Myriad Genetics

BRACAnalysis CDx

FDA hands AstraZeneca and Merck a snap OK to market Lynparza in frontline ovarian cancer, marking a new standard in treatment

Endpoints

Thu, 12/20/18 - 10:01 am

BRCA-mutated ovarian cancer

AstraZeneca mines for positives in Imfinzi's failed Mystic lung cancer trial

Fierce Pharma

Thu, 12/13/18 - 10:07 pm

clinical trials

immuno-oncology

AZ begins liver cancer immunotherapy tie-up with AVEO

Pharmaforum

Thu, 12/13/18 - 10:29 am

cancer immunotherapy

hepatocellular carcinoma

AstraZeneca looks to CRISPR to boost success rates

Pharmaforum

Wed, 12/12/18 - 11:44 am

drug development

AstraZeneca kicks off second blood cancer launch, this time for orphan drug Lumoxiti

Fierce Pharma

Wed, 12/12/18 - 10:05 am

hairy cell leukemia

AstraZeneca's Imfinzi fails another phase 3 trial, this time in head and neck cancer

Fierce Pharma

Fri, 12/7/18 - 12:09 pm

head and neck cancer

clinical trials

AstraZeneca divests asthma and rhinitis drug rights to Covis Pharma

Pharmaceutical Business Review

Thu, 12/6/18 - 11:33 pm

GSK Pays $5.1B For Tesaro, Setting Up “PARP” Battle With Rival AstraZeneca

Xconomy

Mon, 12/3/18 - 10:11 am

PARP inhibitors

Asthma Drug Co-Developed by Dynavax and AstraZeneca Fails to Meet Endpoints in Phase IIa Trial

BioSpace

Fri, 11/30/18 - 10:20 am

clinical trials

Astrazeneca's Fasenra Gets Orphan Drug Designation for Autoimmune Disease

Yahoo/Zacks.com

Tue, 11/27/18 - 12:09 pm

eosinophilic granulomatosis with polyangiitis

Is AstraZeneca looking for the ideal candidate to replace Pascal Soriot?

Endpoints

Mon, 11/19/18 - 11:36 am

Drug Approvals for the 2 Most Common Types of Cancer in the Last 2 Years

BioSpace

Mon, 11/19/18 - 11:29 am

Ariad Pharmaceuticals

Boehringer Ingelheim

Bristol-Myers Squibb

Puma Biotechnology

AstraZeneca may have hit rock bottom, but can it rise to new heights?

Pharmaforum

Sun, 11/18/18 - 12:44 pm

Grünenthal Snaps up Averitas Pharma for Undisclosed Sum to Extend Presence in the U.S.

BioSpace

Sun, 11/18/18 - 12:43 pm

Averitas Pharma

AstraZeneca Shows It Can Still Take Some Knocks

Yahoo/Bloomberg

Sat, 11/17/18 - 12:36 pm

AstraZeneca’s Mystic OS analysis paints tremelimumab as a dud in NSCLC

Fierce Biotech

Fri, 11/16/18 - 12:19 pm

clinical trials

non-small cell lung cancer

Pages